Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
17.84
-0.70 (-3.78%)
At close: Jan 30, 2025, 4:00 PM
17.80
-0.04 (-0.22%)
After-hours: Jan 30, 2025, 5:57 PM EST
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees as of December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$437,082
Profits / Employee
-$43,301
Market Cap
20.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
TEVA News
- 4 hours ago - Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity - Seeking Alpha
- 1 day ago - Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet - Benzinga
- 1 day ago - Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 1 day ago - Teva Pharm Q4 tops estimates on strong sales of its own drugs - Reuters
- 2 days ago - Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data - Benzinga
- 3 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewsWire
- 11 days ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 17 days ago - Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha